|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNM3 |
Gene summary for DNM3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNM3 | Gene ID | 26052 |
| Gene name | dynamin 3 | |
| Gene Alias | Dyna III | |
| Cytomap | 1q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9UQ16 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26052 | DNM3 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 2.73e-09 | 6.13e-01 | -0.2116 |
| 26052 | DNM3 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 8.96e-07 | 7.59e-01 | -0.1941 |
| 26052 | DNM3 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 3.30e-16 | 8.43e-01 | -0.2119 |
| 26052 | DNM3 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 9.20e-18 | 6.31e-01 | -0.0166 |
| 26052 | DNM3 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 4.49e-16 | 5.70e-01 | -0.0132 |
| 26052 | DNM3 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.07e-19 | 6.19e-01 | -0.013 |
| 26052 | DNM3 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.48e-16 | 6.10e-01 | -0.0121 |
| 26052 | DNM3 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.34e-05 | 7.21e-01 | -0.0961 |
| 26052 | DNM3 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 3.18e-02 | 5.48e-01 | -0.0876 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00343297 | Lung | IAC | cell junction assembly | 86/2061 | 420/18723 | 7.98e-09 | 1.10e-06 | 86 |
| GO:00163586 | Lung | IAC | dendrite development | 55/2061 | 243/18723 | 1.35e-07 | 1.18e-05 | 55 |
| GO:00109756 | Lung | IAC | regulation of neuron projection development | 82/2061 | 445/18723 | 1.82e-06 | 8.78e-05 | 82 |
| GO:00068985 | Lung | IAC | receptor-mediated endocytosis | 50/2061 | 244/18723 | 1.01e-05 | 3.23e-04 | 50 |
| GO:00313455 | Lung | IAC | negative regulation of cell projection organization | 41/2061 | 186/18723 | 1.01e-05 | 3.23e-04 | 41 |
| GO:00488134 | Lung | IAC | dendrite morphogenesis | 34/2061 | 146/18723 | 1.68e-05 | 4.79e-04 | 34 |
| GO:00431125 | Lung | IAC | receptor metabolic process | 36/2061 | 166/18723 | 4.93e-05 | 1.13e-03 | 36 |
| GO:00609964 | Lung | IAC | dendritic spine development | 25/2061 | 99/18723 | 5.18e-05 | 1.18e-03 | 25 |
| GO:01200327 | Lung | IAC | regulation of plasma membrane bounded cell projection assembly | 39/2061 | 186/18723 | 5.41e-05 | 1.21e-03 | 39 |
| GO:00604916 | Lung | IAC | regulation of cell projection assembly | 39/2061 | 188/18723 | 6.92e-05 | 1.47e-03 | 39 |
| GO:00313466 | Lung | IAC | positive regulation of cell projection organization | 63/2061 | 353/18723 | 7.37e-05 | 1.55e-03 | 63 |
| GO:00990724 | Lung | IAC | regulation of postsynaptic membrane neurotransmitter receptor levels | 18/2061 | 62/18723 | 8.26e-05 | 1.69e-03 | 18 |
| GO:01060276 | Lung | IAC | neuron projection organization | 23/2061 | 93/18723 | 1.43e-04 | 2.64e-03 | 23 |
| GO:00315032 | Lung | IAC | protein-containing complex localization | 42/2061 | 220/18723 | 2.60e-04 | 4.32e-03 | 42 |
| GO:00990034 | Lung | IAC | vesicle-mediated transport in synapse | 39/2061 | 200/18723 | 2.71e-04 | 4.49e-03 | 39 |
| GO:00970616 | Lung | IAC | dendritic spine organization | 20/2061 | 84/18723 | 6.42e-04 | 8.74e-03 | 20 |
| GO:00991735 | Lung | IAC | postsynapse organization | 33/2061 | 168/18723 | 6.74e-04 | 9.12e-03 | 33 |
| GO:00609983 | Lung | IAC | regulation of dendritic spine development | 16/2061 | 61/18723 | 7.09e-04 | 9.50e-03 | 16 |
| GO:00610013 | Lung | IAC | regulation of dendritic spine morphogenesis | 13/2061 | 47/18723 | 1.29e-03 | 1.45e-02 | 13 |
| GO:00109774 | Lung | IAC | negative regulation of neuron projection development | 27/2061 | 137/18723 | 1.88e-03 | 1.92e-02 | 27 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414414 | Lung | IAC | Endocytosis | 51/1053 | 251/8465 | 2.25e-04 | 2.54e-03 | 1.68e-03 | 51 |
| hsa04072 | Lung | IAC | Phospholipase D signaling pathway | 28/1053 | 148/8465 | 1.46e-02 | 5.00e-02 | 3.32e-02 | 28 |
| hsa0414415 | Lung | IAC | Endocytosis | 51/1053 | 251/8465 | 2.25e-04 | 2.54e-03 | 1.68e-03 | 51 |
| hsa040721 | Lung | IAC | Phospholipase D signaling pathway | 28/1053 | 148/8465 | 1.46e-02 | 5.00e-02 | 3.32e-02 | 28 |
| hsa0510023 | Lung | AIS | Bacterial invasion of epithelial cells | 25/961 | 77/8465 | 6.03e-07 | 2.44e-05 | 1.56e-05 | 25 |
| hsa0414423 | Lung | AIS | Endocytosis | 52/961 | 251/8465 | 9.74e-06 | 3.04e-04 | 1.95e-04 | 52 |
| hsa0510033 | Lung | AIS | Bacterial invasion of epithelial cells | 25/961 | 77/8465 | 6.03e-07 | 2.44e-05 | 1.56e-05 | 25 |
| hsa0414433 | Lung | AIS | Endocytosis | 52/961 | 251/8465 | 9.74e-06 | 3.04e-04 | 1.95e-04 | 52 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNM3 | SNV | Missense_Mutation | c.1075N>A | p.Gly359Ser | p.G359S | Q9UQ16 | protein_coding | deleterious(0.01) | probably_damaging(0.927) | TCGA-A1-A0SN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | ac | SD | |
| DNM3 | SNV | Missense_Mutation | c.2548N>T | p.Arg850Cys | p.R850C | Q9UQ16 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.988) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| DNM3 | SNV | Missense_Mutation | novel | c.2224G>T | p.Ala742Ser | p.A742S | Q9UQ16 | protein_coding | tolerated(1) | benign(0.001) | TCGA-A2-A25D-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| DNM3 | SNV | Missense_Mutation | c.261N>C | p.Lys87Asn | p.K87N | Q9UQ16 | protein_coding | deleterious(0.02) | probably_damaging(0.934) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DNM3 | SNV | Missense_Mutation | c.1417G>A | p.Asp473Asn | p.D473N | Q9UQ16 | protein_coding | tolerated(0.08) | benign(0.071) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DNM3 | SNV | Missense_Mutation | novel | c.1021N>C | p.Glu341Gln | p.E341Q | Q9UQ16 | protein_coding | tolerated(0.15) | benign(0.059) | TCGA-AC-A6NO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DNM3 | SNV | Missense_Mutation | rs368300860 | c.682C>T | p.Arg228Cys | p.R228C | Q9UQ16 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DNM3 | SNV | Missense_Mutation | c.1840N>A | p.Ala614Thr | p.A614T | Q9UQ16 | protein_coding | deleterious(0.01) | possibly_damaging(0.783) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| DNM3 | SNV | Missense_Mutation | novel | c.1282N>A | p.Val428Met | p.V428M | Q9UQ16 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| DNM3 | SNV | Missense_Mutation | c.2438N>G | p.Pro813Arg | p.P813R | Q9UQ16 | protein_coding | tolerated_low_confidence(0.18) | benign(0.219) | TCGA-BH-A1EX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |